Search

Displaying results 3801 - 3810 of 10000 in total
  1. Drug

    GS030-DP

    go.drugbank.com/drugs/DB17847
    Investigational

    It is a component of GS030, an investigational optogenetic treatment, in combination with a medical device GS030-MD.[A259816, L46701] … GS030-DP is an optogenetic gene therapy being investigated for the treatment of retinitis pigmentosa.

  2. Drug

    Mirdametinib

    go.drugbank.com/drugs/DB07101
    ApprovedInvestigational

    [L52485] NF1 is an autosomal-dominant genetic condition caused by loss-of-function variants in the _NF1_ tumour suppressor gene,[A265065,A265070] leading to neurofibromin dysfunction and aberrant activation … On February 11, 2025, mirdametinib was approved by the FDA for the treatment of neurofibromatosis type 1 (NF1).

    Synonyms: N-(((R)-2,3-DIHYDROXYPROPYL)OXY)-3,4-DIFLUORO-2-((2-FLUORO-4-IODOPHENYL)AMINO)BENZAMIDE N-((2R)-2,3-DIHYDROXYPROPOXY)-3,4-DIFLUORO-2-(2-FLUORO-4-IODOANILINO)BENZAMIDE, (-)-N-(((R)-2,3-DIHYDROXYPROPYL)OXY)-3,4-DIFLUORO-2-((2-FLUORO-4-IODOPHENYL)AMINO)BENZAMIDE
  3. Drug

    Ganulameran

    go.drugbank.com/drugs/DB16442
    Investigational

    As such, BNT162b3 has entered a phase I/II study in early September 2020 (NCT04537949). … Pfizer and BioNTech deemed this compound as promising in preclinical trials and have decided to initiate further testing of it.

  4. Drug

    Pyruvic acid

    go.drugbank.com/drugs/DB00119
    ApprovedInvestigationalNutraceutical

    An intermediate compound in the metabolism of carbohydrates, proteins, and fats. In thiamine deficiency, its oxidation is retarded and it accumulates in the tissues, especially in nervous structures. … (From Stedman, 26th ed)

  5. Drug

    Ceruletide

    go.drugbank.com/drugs/DB00403
    Approved

    Caerulein is a specific decapeptide similar in action and composition to the natural gastrointestinal peptide hormone cholecystokinin. … It exerts stimulatory effects on the gastric, biliary, and pancreatic secretion, as well as on certain smooth muscles.

  6. Drug

    Elotuzumab

    go.drugbank.com/drugs/DB06317
    ApprovedInvestigational

    Elotuzumab is a humanized IgG1 (Immunoglobulin G) monoclonal antibody indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received … Elotuzumab is produced in NS0 cells by recombinant DNA technology. Elotuzumab has a theoretical mass of 148.1 kDa for the intact antibody. Elotuzumab was approved on November 30, 2015 by the U.S.

  7. Drug

    MT-0169

    go.drugbank.com/drugs/DB17430
    Investigational

    MT-0169 is a usion protein comprised of an enzymatically active Shiga-like toxin-I A1 subunit fused to a human single chain variable fragment with affinity for human CD38 cell surface protein.

  8. Drug

    Dextrothyroxine

    go.drugbank.com/drugs/DB00509
    ApprovedWithdrawn

    Thyroxine is synthesized via the iodination of tyrosines (monoiodotyrosine) and the coupling of iodotyrosines (diiodotyrosine) in the thyroglobulin. … Thyroxine is peripherally deiodinated to form triiodothyronine which exerts a broad spectrum of stimulatory effects on cell metabolism.

    Products: Choloxin Tab 2mg, Choloxin Tablet 4mg
  9. Drug

    alpha-Arbutin

    go.drugbank.com/drugs/DB14109
    Approved

    Mixtures: Skin White Pro Strength Kojic and Hyaluronic Skin Lightening Serum
  10. Drug

    Datopotamab deruxtecan

    go.drugbank.com/drugs/DB16410
    ApprovedInvestigational

    [L52130,L52220] In June 2025, it was granted an accelerated approval by the FDA for the treatment non-small cell lung cancers with EGFR mutations.[L53623] … [L52215] Datopotamab deruxtecan-dlnk (Datroway) was approved by the US FDA in January 2025 for the treatment of hormone receptor positive, HER2 negative unresectable or metastatic breast cancer.